RVTY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVTY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Revvity's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 5.88%.
Revvity's EBITDA per Share for the three months ended in Mar. 2024 was $1.35.
The historical data trend for Revvity's YoY EBITDA Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
YoY EBITDA Growth | Get a 7-Day Free Trial | 1.92 | 103.18 | 47.75 | -32.50 | -38.89 |
Revvity Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
YoY EBITDA Growth | Get a 7-Day Free Trial | -55.48 | -39.11 | -11.77 | -37.65 | 5.88 |
YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.
Revvity's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:
YoY EBITDA Growth (A: Dec. 2023 ) | |||||
= | (EBITDA per Share (A: Dec. 2023 ) | - | EBITDA per Share (A: Dec. 2022 )) | / | | EBITDA per Share (A: Dec. 2022 ) | |
= | (5.717 | - | 9.356) | / | | 9.356 | |
= | -38.89 % |
Revvity's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:
YoY EBITDA Growth (Q: Mar. 2024 ) | |||||
= | (EBITDA per Share (Q: Mar. 2024 ) | - | EBITDA per Share (Q: Mar. 2023 )) | / | | EBITDA per Share (Q: Mar. 2023 )) | |
= | (1.35 | - | 1.275) | / | | 1.275 | |
= | 5.88 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Revvity's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Anita Gonzales | officer: Please See Remarks | 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457 |
Andrew Okun | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451 |
Maxwell Krakowiak | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457 |
Daniel R Tereau | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451 |
Tajinder Vohra | officer: Please See Remarks | 940 WINTER STREET, WALTHAM MA 02451-1457 |
Prahlad R. Singh | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457 |
Joel S Goldberg | officer: See Remarks | 940 WINTER STREET, WALTHAM MA 02451 |
Michelle Mcmurry-heath | director | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
James M Mock | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451 |
Sylvie Gregoire | director | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Miriame Victor | officer: Please See Remarks | 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457 |
Peter Barrett | director | C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142 |
Michel Vounatsos | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Alexis P Michas | director | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Pascale Witz | director | C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.